NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ)
$0.1318 -0.0582 (-30.6316%)
Analysed NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) News Sources
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
10-09-2025
yahoo.com
Sector Update: Health Care Stocks Retreat Late Afternoon
10-09-2025
yahoo.com
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
06-10-2025
yahoo.com
NeuroSense to Host Investor Webinar on December 8, 2025
03-11-2025
yahoo.com
/C O R R E C T I O N -- NeuroSense/
18-03-2026
yahoo.com
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
24-03-2026
yahoo.com
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
31-03-2026
yahoo.com
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
03-04-2026
yahoo.com
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
06-04-2026
yahoo.com
NeuroSense Announces Pricing of Insider-Led PIPE Financing
28-04-2026
yahoo.com
What is the current price of NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ)?
The current price of NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) is $0.1318.
NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) absolute price change since previous trading day?
The absolute price change of NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) since the previous trading day is $-0.0582.
NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) percentage price change since previous trading day?
The percentage price change of NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) since the previous trading day is -30.6316%.
What is the most recent average sentiment score for NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ)?
The most recent average sentiment score for NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) is 67 out of 100.
What is the most recent average sentiment for NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ)?
The most recent sentiment for NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) is .
SEC-8K** Filing Available For NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.